HighMark Wealth Management LLC Buys 10,000 Shares of MiMedx Group, Inc $MDXG

HighMark Wealth Management LLC lifted its position in MiMedx Group, Inc (NASDAQ:MDXG) by 23.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. HighMark Wealth Management LLC’s holdings in MiMedx Group were worth $324,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in MDXG. OneDigital Investment Advisors LLC grew its holdings in MiMedx Group by 3.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company’s stock valued at $419,000 after buying an additional 2,056 shares in the last quarter. Rhumbline Advisers boosted its position in shares of MiMedx Group by 1.4% during the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock valued at $1,346,000 after acquiring an additional 2,436 shares during the last quarter. Isthmus Partners LLC grew its holdings in shares of MiMedx Group by 1.1% in the first quarter. Isthmus Partners LLC now owns 310,262 shares of the company’s stock valued at $2,358,000 after purchasing an additional 3,455 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MDXG shares. Cantor Fitzgerald increased their price objective on shares of MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. Wall Street Zen raised shares of MiMedx Group from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Price Performance

MDXG opened at $6.71 on Friday. The business has a fifty day moving average of $7.05 and a 200 day moving average of $6.87. The stock has a market cap of $992.81 million, a P/E ratio of 31.95 and a beta of 1.73. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08. MiMedx Group, Inc has a 52-week low of $5.47 and a 52-week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The business had revenue of $98.61 million during the quarter, compared to the consensus estimate of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. As a group, sell-side analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.